Table 1 Study population.
| Diagnosis | Sample | Sex | Age (years) | SpA | Gut histology | Clinical CD | CD location | Drug | |
|---|---|---|---|---|---|---|---|---|---|
| Macroarrays | Control | 1 | F | 59 | No | Normal | No | – | |
| 2 | F | 45 | No | Normal | No | – | |||
| 3 | F | 55 | No | Normal | No | – | |||
| 4 | M | 30 | No | Normal | No | – | |||
| 5 | F | 58 | No | Normal | No | – | |||
| 6 | M | 40 | No | Normal | No | – | |||
| CD | 7 | M | 21 | No | Chronic | Yes | IC | – | |
| 8 | F | 48 | No | Chronic | Yes | IC | 5‐ASA | ||
| 9 | F | 41 | Yes | Chronic | Yes | C | – | ||
| 10 | F | 23 | No | Chronic | Yes | C | AZA | ||
| SpA | 11 | M | 47 | Yes | Normal | No | – | ||
| 12 | F | 85 | Yes | Normal | No | – | |||
| 13 | F | 60 | Yes | Normal | No | – | |||
| 14 | F | 43 | Yes | Chronic | Yes | – | |||
| Microarrays | Control | 1 | M | 54 | No | Normal | No | – | |
| 2 | F | 64 | No | Normal | No | – | |||
| 3 | F | 72 | No | Normal | No | – | |||
| 4 | M | 51 | No | Normal | No | – | |||
| 5 | F | 21 | No | Normal | No | – | |||
| 6 | F | 68 | No | Normal | No | – | |||
| 7 | F | 32 | No | Normal | No | – | |||
| 8 | F | 73 | No | Normal | No | – | |||
| 9 | F | 66 | No | Normal | No | – | |||
| 10 | M | 76 | No | Normal | No | – | |||
| CD | 11 | F | 23 | No | Chronic | Yes | IC | 5‐ASA | |
| 12 | F | 39 | Yes | Chronic | Yes | C | – | ||
| 13 | M | 51 | No | Chronic | Yes | C | – | ||
| 14 | M | 43 | No | Chronic | Yes | I | – | ||
| 15 | M | 36 | No | Chronic | Yes | IC | – | ||
| 16 | F | 27 | No | Chronic | Yes | IC | – | ||
| 17 | F | 46 | Yes | Chronic | Yes | IC | AZA | ||
| 18 | F | 23 | No | Chronic | Yes | IC | – | ||
| 19 | M | 19 | No | Chronic | Yes | IC | – | ||
| 20 | F | 26 | No | Chronic | Yes | IC | – | ||
| 21 | F | 36 | No | Chronic | Yes | IC | – | ||
| SpA | 22 | M | 40 | AS periph | Acute | No | – | ||
| 23 | M | 29 | AS periph | Normal | No | NSAID | |||
| 24 | M | 42 | AS periph | Acute | No | – | |||
| 25 | M | 31 | AS periph | Acute | No | NSAID | |||
| 26 | M | 76 | USpA | Normal | No | Steroids | |||
| 27 | F | 28 | AS ax | Normal | No | NSAID | |||
| 28 | M | 58 | AS periph | Normal | No | – | |||
| 29 | M | 38 | AS ax | Normal | No | Sulfa | |||
| 30 | F | 49 | AS periph | Chronic | No | Sulfa | |||
| 31 | M | 49 | AS periph | Chronic | No | – | |||
| 32 | M | 45 | AS periph | Chronic | No | Sulfa | |||
| 33 | M | 29 | USpA | Acute | No | Sulfa+NSAID | |||
| 34 | M | 48 | AS periph | Normal | No | NSAID | |||
| 35 | F | 44 | AS periph | Chronic | Yes | IC | Sulfa+AZA | ||
| 36 | M | 36 | AS ax | Normal | No | Sulfa+NSAID |
5‐ASA, 5‐aminosalicylates; AS ax, ankylosing spondylitis with only axial involvement; AS periph, ankylosing spondylitis with peripheral involvement; AZA, azathioprine; C, colonic involvement only; CD, Crohn's disease; F, female; I, ileal involvement only; IC, ileocolonic; M, male; NSAID, non‐steroidal anti‐inflammatory drug; SpA, spondyloarthropathy; Sulfa, sulfasalazine; USpA, undifferentiated SpA.
Histology of patients with SpA is a historical classification.